REFERENCES
1. Richman TR, Ermer JA, Baker J, et al. Mitochondrial gene expression is required for platelet function and blood clotting. Cell Rep. 2023;42:113312.
2. Bergmeier W, Hynes RO. Extracellular matrix proteins in hemostasis and thrombosis. Cold Spring Harb Perspect Biol. 2012;4:a005132.
3. Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. 2023;23:495-510.
4. Zou CY, Li QJ, Hu JJ, et al. Design of biopolymer-based hemostatic material: starting from molecular structures and forms. Mater Today Bio. 2022;17:100468.
5. Leung J, Strong C, Badior KE, et al. Genetically engineered transfusable platelets using mRNA lipid nanoparticles. Sci Adv. 2023;9:eadi0508.
6. Caudrillier A, Kessenbrock K, Gilliss BM, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest. 2012;122:2661-71.
8. Li X, Fries S, Li R, et al. Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2014;111:16830-5.
9. Tyagi T, Jain K, Gu SX, et al. A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. Nat Cardiovasc Res. 2022;1:223-37.
10. Fang J, Wang X, Jiang W, et al. Platelet-rich plasma therapy in the treatment of diseases associated with orthopedic injuries. Tissue Eng Part B Rev. 2020;26:571-85.
11. Wang T, Yi W, Zhang Y, et al. Sodium alginate hydrogel containing platelet-rich plasma for wound healing. Colloids Surf B Biointerfaces. 2023;222:113096.
12. Wu J, Piao Y, Liu Q, Yang X. Platelet-rich plasma-derived extracellular vesicles: a superior alternative in regenerative medicine? Cell Prolif. 2021;54:13123.
13. White JG, Krumwiede MD, Cocking-Johnson DJ, Escolar G. Dynamic redistribution of glycoprotein Ib/IX on surface-activated platelets. A second look. Am J Pathol. 1995;147:1057-67.
14. White JG, Escolar G. Current concepts of platelet membrane response to surface activation. Platelets. 1993;4:175-89.
15. Sixma JJ, Slot JW, Geuze HJ. [26]Immunocytochemical localization of platelet granule proteins. Methods Enzymol. 1989;169:301-11.
17. Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem. 2004;279:44250-7.
19. White JG, Krivit W. An ultrastructural basis for the shape changes induced in platelets by chilling. Blood. 1967;30:625-35.
20. Escolar G, Krumwiede M, White JG. Organization of the actin cytoskeleton of resting and activated platelets in suspension. Am J Pathol. 1986;123:86-94.
22. Gerrard JM, White JG, Peterson DA. The platelet dense tubular system: its relationship to prostaglandin synthesis and calcium flux. Thromb Haemost. 1978;40:224-31.
24. Noetzli LJ, French SL, Machlus KR. New insights into the differentiation of megakaryocytes from hematopoietic progenitors. Arterioscler Thromb Vasc Biol. 2019;39:1288-300.
26. Long MW, Williams N, Ebbe S. Immature megakaryocytes in the mouse: physical characteristics, cell cycle status, and in vitro responsiveness to thrombopoietic stimulatory factor. Blood. 1982;59:569-75.
27. Machlus KR, Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol. 2013;201:785-96.
28. Bender M, Thon JN, Ehrlicher AJ, et al. Microtubule sliding drives proplatelet elongation and is dependent on cytoplasmic dynein. Blood. 2015;125:860-8.
29. Thon JN, Montalvo A, Patel-Hett S, et al. Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol. 2010;191:861-74.
30. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568-71.
31. Zhang L, Orban M, Lorenz M, et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med. 2012;209:2165-81.
32. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14:943-51.
33. Fujii T, Sakata A, Nishimura S, Eto K, Nagata S. TMEM16F is required for phosphatidylserine exposure and microparticle release in activated mouse platelets. Proc Natl Acad Sci U S A. 2015;112:12800-5.
34. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature. 2010;468:834-8.
35. van Kruchten R, Mattheij NJ, Saunders C, et al. Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood. 2013;121:1850-7.
36. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114:663-6.
37. Minamikawa T, Williams DA, Bowser DN, Nagley P. Mitochondrial permeability transition and swelling can occur reversibly without inducing cell death in intact human cells. Exp Cell Res. 1999;246:26-37.
38. Jansen AJ, Josefsson EC, Rumjantseva V, et al. Desialylation accelerates platelet clearance after refrigeration and initiates GPIbα metalloproteinase-mediated cleavage in mice. Blood. 2012;119:1263-73.
39. Yang X, Liu W, Li N, et al. Design and development of polysaccharide hemostatic materials and their hemostatic mechanism. Biomater Sci. 2017;5:2357-68.
40. Sørensen AL, Rumjantseva V, Nayeb-Hashemi S, et al. Role of sialic acid for platelet life span: exposure of β-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood. 2009;114:1645-54.
41. Josefsson EC, Gebhard HH, Stossel TP, Hartwig JH, Hoffmeister KM. The macrophage αMβ2 integrin αM lectin domain mediates the phagocytosis of chilled platelets. J Biol Chem. 2005;280:18025-32.
42. Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80:33-40.
43. Deng W, Xu Y, Chen W, et al. Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. Nat Commun. 2016;7:12863.
44. Yan R, Chen M, Ma N, et al. Glycoprotein Ibα clustering induces macrophage-mediated platelet clearance in the liver. Thromb Haemost. 2015;113:107-17.
45. Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor γ-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem. 1997;272:23528-31.
46. Worth RG, Chien CD, Chien P, Reilly MP, McKenzie SE, Schreiber AD. Platelet FcγRIIA binds and internalizes IgG-containing complexes. Exp Hematol. 2006;34:1490-5.
47. Boulaftali Y, Hess PR, Getz TM, et al. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest. 2013;123:908-16.
48. Quek LS, Pasquet JM, Hers I, et al. Fyn and Lyn phosphorylate the Fc receptor γ chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Blood. 2000;96:4246-53.
49. Delaney MK, Kim K, Estevez B, et al. Differential roles of the NADPH-oxidase 1 and 2 in platelet activation and thrombosis. Arterioscler Thromb Vasc Biol. 2016;36:846-54.
50. Wang D, Feng J, Wen R, et al. Phospholipase Cγ2 is essential in the functions of B cell and several Fc receptors. Immunity. 2000;13:25-35.
51. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost. 2010;8:1456-67.
53. Ozaki Y, Suzuki-Inoue K, Inoue O. Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2. J Thromb Haemost. 2013;11 Suppl 1:330-9.
54. Gowert NS, Krüger I, Klier M, et al. Loss of Reelin protects mice against arterial thrombosis by impairing integrin activation and thrombus formation under high shear conditions. Cell Signal. 2017;40:210-21.
55. Tseng WL, Huang CL, Chong KY, et al. Reelin is a platelet protein and functions as a positive regulator of platelet spreading on fibrinogen. Cell Mol Life Sci. 2010;67:641-53.
56. Huang J, Li X, Shi X, et al. Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting. J Hematol Oncol. 2019;12:26.
58. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-9.
59. BORN GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927-9.
60. Fabre JE, Nguyen M, Latour A, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999;5:1199-202.
61. Moers A, Wettschureck N, Grüner S, Nieswandt B, Offermanns S. Unresponsiveness of platelets lacking both Gαq and Gα13. Implications for collagen-induced platelet activation. J Biol Chem. 2004;279:45354-9.
62. Cho MJ, Liu J, Pestina TI, et al. The roles of αIIbβ3-mediated outside-in signal transduction, thromboxane A2, and adenosine diphosphate in collagen-induced platelet aggregation. Blood. 2003;101:2646-51.
63. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol. 1999;144:745-54.
64. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A. 1994;91:504-8.
65. Moers A, Nieswandt B, Massberg S, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med. 2003;9:1418-22.
66. Bauer M, Retzer M, Wilde JI, et al. Dichotomous Regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood. 1999;94:1665-72.
67. Paul BZ, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem. 1999;274:28293-300.
68. Morgenstern E, Neumann K, Patscheke H. The exocytosis of human blood platelets. A fast freezing and freeze-substitution analysis. Eur J Cell Biol. 1987;43:273-82.
69. Reed GL, Fitzgerald ML, Polgár J. Molecular mechanisms of platelet exocytosis: insights into the “secrete” life of thrombocytes. Blood. 2000;96:3334-42.
70. Feng D, Crane K, Rozenvayn N, Dvorak AM, Flaumenhaft R. Subcellular distribution of 3 functional platelet SNARE proteins: human cellubrevin, SNAP-23, and syntaxin 2. Blood. 2002;99:4006-14.
71. Yadav S, Storrie B. The cellular basis of platelet secretion: emerging structure/function relationships. Platelets. 2017;28:108-18.
72. Stenberg PE, Shuman MA, Levine SP, Bainton DF. Redistribution of alpha-granules and their contents in thrombin-stimulated platelets. J Cell Biol. 1984;98:748-60.
73. Harrison P, Savidge GF, Cramer EM. The origin and physiological relevance of alpha-granule adhesive proteins. Br J Haematol. 1990;74:125-30.
74. Handagama PJ, George JN, Shuman MA, McEver RP, Bainton DF. Incorporation of a circulating protein into megakaryocyte and platelet granules. Proc Natl Acad Sci U S A. 1987;84:861-5.
75. Heijnen HFG, Debili N, Vainchencker W, et al. Multivesicular bodies are an intermediate stage in the formation of platelet alpha-granule. Blood. 1998;91:2313-25.
76. Harrison P, Wilbourn B, Debili N, et al. Uptake of plasma fibrinogen into the α granules of human megakaryocytes and platelets. J Clin Invest. 1989;84:1320-4.
77. Berger G, Massé JM, Cramer EM. Alpha-granule membrane mirrors the platelet plasma membrane and contains the glycoproteins Ib, IX, and V. Blood. 1996;87:1385-95.
78. Suzuki H, Murasaki K, Kodama K, Takayama H. Intracellular localization of glycoprotein VI in human platelets and its surface expression upon activation. Br J Haematol. 2003;121:904-12.
79. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116:3211-9.
80. Youssefian T, Cramer EM. Megakaryocyte dense granule components are sorted in multivesicular bodies. Blood. 2000;95:4004-7.
81. Cramer EM, Norol F, Guichard J, et al. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood. 1997;89:2336-46.
82. Fukami MH, Holmsen H, Ugurbil K. Histamine uptake in pig platelets and isolated dense granules. Biochem Pharmacol. 1984;33:3869-74.
83. Chang H, Yanachkov IB, Michelson AD, et al. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010;125:159-65.
84. Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 2001;12:261-73.
85. Karampini E, Bierings R, Voorberg J. Orchestration of primary hemostasis by platelet and endothelial lysosome-related organelles. Arterioscler Thromb Vasc Biol. 2020;40:1441-53.
86. Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50:326-36.
87. Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133-48.
88. Mackie IJ, Jones R, Machin SJ. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J Clin Pathol. 1984;37:874-8.
89. Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781-8.
90. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost. 2009;35:158-67.
91. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620-5.
92. Podda G, Femia EA, Pugliano M, Cattaneo M. Congenital defects of platelet function. Platelets. 2012;23:552-63.
93. Görlinger K, Dirkmann D, Solomon C, Hanke AA. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. Br J Anaesth. 2013;110:222-30.
95. Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med. 2011;12:312-22.
96. Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93:327-58.
97. Weisel JW, Litvinov RI. Red blood cells: the forgotten player in hemostasis and thrombosis. J Thromb Haemost. 2019;17:271-82.
98. Drakeford C, Aguila S, Roche F, et al. von Willebrand factor links primary hemostasis to innate immunity. Nat Commun. 2022;13:6320.
99. Klatt C, Krüger I, Zey S, et al. Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis. J Clin Invest. 2018;128:3906-25.
100. Knight CG, Morton LF, Peachey AR, Tuckwell DS, Farndale RW, Barnes MJ. The collagen-binding A-domains of integrins α1β1 and α2β1 recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J Biol Chem. 2000;275:35-40.
101. Wang XX, Liu Q, Sui JX, et al. Recent advances in hemostasis at the nanoscale. Adv Healthc Mater. 2019;8:1900823.
102. Yeung J, Li W, Holinstat M. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases. Pharmacol Rev. 2018;70:526-48.
103. Huang Z, Zhang D, Tong L, et al. Protonated-chitosan sponge with procoagulation activity for hemostasis in coagulopathy. Bioact Mater. 2024;41:174-92.
104. Hickman DA, Pawlowski CL, Sekhon UDS, Marks J, Gupta AS. Biomaterials and advanced technologies for hemostatic management of bleeding. Adv Mater. 2018;30:1700859.
105. Koupenova M, Livada AC, Morrell CN. Platelet and megakaryocyte roles in innate and adaptive immunity. Circ Res. 2022;130:288-308.
106. Habets KL, Huizinga TW, Toes RE. Platelets and autoimmunity. Eur J Clin Invest. 2013;43:746-57.
107. Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev. 2015;29:153-62.
108. Scopelliti F, Cattani C, Dimartino V, Mirisola C, Cavani A. Platelet derivatives and the immunomodulation of wound healing. Int J Mol Sci. 2022;23:8370.
109. Stocker TJ, Ishikawa-Ankerhold H, Massberg S, Schulz C. Small but mighty: platelets as central effectors of host defense. Thromb Haemost. 2017;117:651-61.
110. Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost. 2014;12:1764-75.
111. Tsai WC, Yu TY, Chang GJ, Lin LP, Lin MS, Pang JS. Platelet-rich plasma releasate promotes regeneration and decreases inflammation and apoptosis of injured skeletal muscle. Am J Sports Med. 2018;46:1980-6.
112. Kasperska-Zajac A, Rogala B. Platelet activation during allergic inflammation. Inflammation. 2007;30:161-6.
113. Zhou Z, Luo R, Chen L, et al. Dressing blood-contacting devices with platelet membrane enables large-scale multifunctional biointerfacing. Matter. 2022;5:2334-51.
114. Stellos K, Kopf S, Paul A, et al. Platelets in regeneration. Semin Thromb Hemost. 2010;36:175-84.
115. Shido K, Chavez D, Cao Z, Ko J, Rafii S, Ding BS. Platelets prime hematopoietic and vascular niche to drive angiocrine-mediated liver regeneration. Signal Transduct Target Ther. 2017;2:16044-.
116. Tian Y, Zong Y, Pang Y, et al. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther. 2025;10:159.
117. Tang L, Cai S, Lu X, et al. Platelet-derived growth factor nanocapsules with tunable controlled release for chronic wound healing. Small. 2024;20:2310743.
118. Gao J, Lan T, Kostallari E, et al. Angiocrine signaling in sinusoidal homeostasis and liver diseases. J Hepatol. 2024;81:543-61.
119. Meyer J, Lejmi E, Fontana P, Morel P, Gonelle-Gispert C, Bühler L. A focus on the role of platelets in liver regeneration: do platelet-endothelial cell interactions initiate the regenerative process? J Hepatol. 2015;63:1263-71.
121. Lu S, Wang R, Cai M, et al. Platelet membrane decorated exosomes enhance targeting efficacy and therapeutic index to alleviate arterial restenosis. Theranostics. 2025;15:408-27.
122. Turner ME, Che J, Leland JT, et al. Modulating the platelet-mediated innate foreign body response to affect in situ vascular tissue engineering outcomes. NPJ Regen Med. 2025;10:34.
123. Lena F. Hemostatic polymers: the concept, state of the art and perspectives. J Mater Chem B. 2014;2:3567-77.
124. Zhu Q, Chen Z, Wang D, et al. Microenvironment-responsive coating for vascular stents to regulate coagulation-inflammation interaction and promote vascular recovery. Bioact Mater. 2025;48:443-57.
125. Jiang X, Wong KHK, Khankhel AH, et al. Microfluidic isolation of platelet-covered circulating tumor cells. Lab Chip. 2017;17:3498-503.
126. Li S, Lu Z, Wu S, et al. The dynamic role of platelets in cancer progression and their therapeutic implications. Nat Rev Cancer. 2024;24:72-87.
127. Lebaudy E, Fournel S, Lavalle P, Vrana NE, Gribova V. Recent advances in antiinflammatory material design. Adv Healthc Mater. 2021;10:2001373.
128. Huang J, Jiang Y, Liu Y, et al. Marine-inspired molecular mimicry generates a drug-free, but immunogenic hydrogel adhesive protecting surgical anastomosis. Bioact Mater. 2021;6:770-82.
129. Gebremeskel S, LeVatte T, Liwski RS, Johnston B, Bezuhly M. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015;136:234-40.
130. Zhang W, Dang S, Hong T, et al. A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment. Blood. 2012;120:2889-98.
131. Liu X, Chen W, Shao B, et al. Mussel patterned with 4D biodegrading elastomer durably recruits regenerative macrophages to promote regeneration of craniofacial bone. Biomaterials. 2021;276:120998.
132. Luo L, Zhang B, Tao F, et al. Perfluorotributylamine-loaded albumin nanoparticles downregulate platelet-derived TGFβ to inhibit tumor metastasis. ACS Nano. 2023;17:15388-400.
133. Hou Y, Jiang N, Zhang L, et al. Oppositely charged polyurethane microspheres with tunable zeta potentials as an injectable dual-loaded system for bone repair. ACS Appl Mater Interfaces. 2017;9:25808-17.
134. Ye R, Zhu Z, Gu T, et al. Neutrophil extracellular traps-inspired DNA hydrogel for wound hemostatic adjuvant. Nat Commun. 2024;15:5557.
135. Pourshahrestani S, Zeimaran E, Kadri NA, Mutlu N, Boccaccini AR. Polymeric hydrogel systems as emerging biomaterial platforms to enable hemostasis and wound healing. Adv Healthc Mater. 2020;9:2000905.
136. Wang Y, Zhang S, Luo L, et al. Platelet-derived microparticles regulates thrombin generation via phophatidylserine in abdominal sepsis. J Cell Physiol. 2018;233:1051-60.
137. Guo B, Dong R, Liang Y, Li M. Haemostatic materials for wound healing applications. Nat Rev Chem. 2021;5:773-91.
138. Zou CY, Han C, Xiong M, et al. All-in-one extracellular matrix-based powders with instant self-assembly and multiple bioactivities integrate hemostasis and in-situ tissue functional repair. Bioact Mater. 2025;50:215-31.
139. Qin X, Labuda K, Chen J, et al. Development of synthetic platelet-activating hydrogel matrices to induce local hemostasis. Adv Funct Materials. 2015;25:6606-17.
140. Du X, Wu L, Yan H, et al. Microchannelled alkylated chitosan sponge to treat noncompressible hemorrhages and facilitate wound healing. Nat Commun. 2021;12:4733.
141. Lei XX, Zou CY, Hu JJ, et al. A self-assembly pro-coagulant powder capable of rapid gelling transformation and wet adhesion for the efficient control of non-compressible hemorrhage. Adv Sci. 2024;11:2306289.
142. Jiang Y, Wang J, Zhang H, Chen G, Zhao Y. Bio-inspired natural platelet hydrogels for wound healing. Sci Bull. 2022;67:1776-84.
144. Li Y, Li X, Chen T, Li J, Qi J, Li W. A programmable platelet theranostic platform for adaptive multi-stage delivery and synergistic immunotherapy in atherosclerosis. Nat Commun. 2025;16:6445.
145. Liu Z, Liu F, Feng D, et al. Microwave-responsive engineered platelet microneedle patch for deep tumor penetration and precision therapy. ACS Appl Mater Interfaces. 2025;17:10457-69.
146. Chen Y, Pal S, Li W, Liu F, Yuan S, Hu Q. Engineered platelets as targeted protein degraders and application to breast cancer models. Nat Biotechnol. 2025;43:1800-12.
147. Wang C, Sun W, Ye Y, Hu Q, Bomba HN, Gu Z. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat Biomed Eng. 2017;1:BFs415510160011.
148. Yuan G, Yu C, Du X, et al. Injectable GelMA hydrogel microspheres with sustained release of platelet-rich plasma for the treatment of thin endometrium. Small. 2024;20:2403890.
149. Qi J, Li X, Cao Y, et al. Locationally activated PRP via an injectable dual-network hydrogel for endometrial regeneration. Biomaterials. 2024;309:122615.
150. Antich-Rosselló M, Forteza-Genestra MA, Monjo M, Ramis JM. Platelet-derived extracellular vesicles for regenerative medicine. Int J Mol Sci. 2021;22:8580.
151. Johnson J, Wu YW, Blyth C, Lichtfuss G, Goubran H, Burnouf T. Prospective therapeutic applications of platelet extracellular vesicles. Trends Biotechnol. 2021;39:598-612.
152. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582-8.
153. Johnson J, Law SQK, Shojaee M, et al. First-in-human clinical trial of allogeneic, platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing. J Extracell Vesicles. 2023;12:12332.
154. Liu GS, Chen HA, Chang CY, et al. Platelet-derived extracellular vesicle drug delivery system loaded with kaempferol for treating corneal neovascularization. Biomaterials. 2025;319:123205.
155. Lu J, Yang X, He C, et al. Rejuvenation of tendon stem/progenitor cells for functional tendon regeneration through platelet-derived exosomes loaded with recombinant Yap1. Acta Biomater. 2023;161:80-99.
156. Yang P, Zhang J, Xiang S, et al. Green nanoparticle scavengers against oxidative stress. ACS Appl Mater Interfaces. 2021;13:39126-34.
157. Ma Q, Fan Q, Xu J, et al. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles. Matter. 2020;3:287-301.
158. Yao C, Ma Q, Wang H, et al. Targeting myeloid cells with platelet-derived extracellular vesicles to overcome resistance of immune checkpoint blockade therapy. Biomaterials. 2025;321:123336.
159. Wei A, Ding T, Li G, et al. Activated platelet membrane vesicles for broad-spectrum bacterial pulmonary infections management. J Control Release. 2025;380:846-59.
160. Zhang M, Li Y, Xu T, et al. A rapamycin-loading platelet membrane hybrid liposome with anti-inflammation effect and long-lasting repair capability for acute kidney injury. J Control Release. 2025;380:927-42.
161. Sun D, Zhang H, Li D, et al. Platelet membrane-camouflaged ROS-responsive nanoplatform for targeted delivery and sustained release of verteporfin to modulate hippo signaling pathway in glaucoma therapy. Adv Funct Mater. 2025;35:e10931.
162. Hu CM, Fang RH, Wang KC, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526:118-21.
163. Li M, Xu X, Tang G, et al. Modular assembled biomimetic nanobubbles for synergistic therapy of ischemic stroke via cascade modulation thrombo-inflammatory network. Bioact Mater. 2025;52:753-72.
164. Liu H, Cai Z, Wang F, et al. Platelet membrane fragment self-assembled oral hydrogel microspheres for restoring intestinal microvascular injury. Adv Funct Mater. 2023;33:2302007.
165. Xu X, Zhang X, Li R, et al. Platelet membrane-coated curcumin-PLGA nanoparticles promote astrocyte-neuron transdifferentiation for intracerebral hemorrhage treatment. Small. 2024;20:2311128.
166. Zhang L, Gong H, Gong X, et al. Bioengineered platelet nanoplatform enables renal-targeted dexamethasone delivery for chronic nephritis therapy with dual anti-inflammatory/anti-fibrotic effects and minimized systemic toxicity. Bioact Mater. 2025;52:213-27.
167. Li Q, Huang Z, Wang Q, et al. Targeted immunomodulation therapy for cardiac repair by platelet membrane engineering extracellular vesicles via hitching peripheral monocytes. Biomaterials. 2022;284:121529.
168. Wang H, Zhu Y, Zhang L, et al. Nanoplateletsomes for rapid hemostasis performance. Chinese Chemical Letters. 2022;33:2937-41.
169. Hu H, Hua SY, Lin X, et al. Hybrid biomimetic membrane coated particles-mediated bacterial ferroptosis for acute MRSA pneumonia. ACS Nano. 2023;17:11692-712.
170. Zhang S, Chen T, Lu W, Lin Y, Zhou M, Cai X. Hybrid cell membrane-engineered nanocarrier for triple-action strategy to address pseudomonas aeruginosa infection. Adv Sci. 2025;12:2411261.
171. Papa AL, Jiang A, Korin N, et al. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019;11:eaau5898.
172. Raghunathan S, Rayes J, Sen Gupta A. Platelet-inspired nanomedicine in hemostasis thrombosis and thromboinflammation. J Thromb Haemost. 2022;20:1535-49.
173. Li Z, Hu S, Cheng K. Platelets and their biomimetics for regenerative medicine and cancer therapies. J Mater Chem B. 2018;6:7354-65.
174. Yan J, Wang Y, Li X, et al. A bionic nano-band-aid constructed by the three-stage self-assembly of peptides for rapid liver hemostasis. Nano Lett. 2021;21:7166-74.
175. Gao Y, Sarode A, Kokoroskos N, et al. A polymer-based systemic hemostatic agent. Sci Adv. 2020;6:eaba0588.
176. Feng Y, Zhang Z, Yan W, et al. A sprayable hydrogel based on biomimetic polypeptide-modified lipid nanoparticles for treating non-compressible hemorrhaging. Adv Mater. 2025;37:2500908.
177. Nellenbach K, Mihalko E, Nandi S, et al. Ultrasoft platelet-like particles stop bleeding in rodent and porcine models of trauma. Sci Transl Med. 2024;16:eadi4490.
178. He Y, Xu J, Sun X, et al. Cuboidal tethered cyclodextrin frameworks tailored for hemostasis and injured vessel targeting. Theranostics. 2019;9:2489-504.
179. Chen T, Xiao C, Chen X, et al. Covalently reactive microparticles imbibe blood to form fortified clots for rapid hemostasis and prevention of rebleeding. Nat Commun. 2025;16:3705.
180. Zeng Y, Yang S, Tian Z, et al. A platelet-substitute-releasing supramolecular material for cellular assembly mediated on-demand hemostasis. Adv Funct Mater. 2025;35:2422686.
181. Cecerska-Heryć E, Goszka M, Serwin N, et al. Applications of the regenerative capacity of platelets in modern medicine. Cytokine Growth Factor Rev. 2022;64:84-94.
182. Taschieri S, Lolato A, Ofer M, Testori T, Francetti L, Del Fabbro M. Immediate post-extraction implants with or without pure platelet-rich plasma: a 5-year follow-up study. Oral Maxillofac Surg. 2017;21:147-57.
183. Xu J, Gou L, Zhang P, Li H, Qiu S. Platelet-rich plasma and regenerative dentistry. Aust Dent J. 2020;65:131-42.
184. Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE. A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J Periodontol. 1997;68:1186-93.
185. Mohammadi MH, Molavi B, Mohammadi S, et al. Evaluation of wound healing in diabetic foot ulcer using platelet-rich plasma gel: a single-arm clinical trial. Transfus Apher Sci. 2017;56:160-4.
186. García-Conca V, Abad-Collado M, Hueso-Abancens JR, et al. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol. 2019;97:e170-8.
187. Doria C, Mosele GR, Caggiari G, Puddu L, Ciurlia E. Treatment of early hip osteoarthritis: ultrasound-guided platelet rich plasma versus hyaluronic acid injections in a randomized clinical trial. Joints. 2017;5:152-5.
188. Łukasik ZM, Makowski M, Makowska JS. From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders. Rheumatol Int. 2018;38:959-74.
189. Eriksson O, Mohlin C, Nilsson B, Ekdahl KN. The human platelet as an innate immune cell: interactions between activated platelets and the complement system. Front Immunol. 2019;10:1590.
190. Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol Surg. 2005;31:674-86.
191. Nurden AT. The biology of the platelet with special reference to inflammation, wound healing and immunity. Front Biosci. 2018;23:726-51.
192. Senior RM, Griffin GL, Huang JS, Walz DA, Deuel TF. Chemotactic activity of platelet alpha granule proteins for fibroblasts. J Cell Biol. 1983;96:382-5.
193. Chen Z, Luo J, Li J, et al. Intestinal IL-33 promotes platelet activity for neutrophil recruitment during acute inflammation. Blood. 2022;139:1878-91.
